The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated survival date of phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer.
 
Atsushi Horiike
Honoraria - A2 Healthcare; AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; MSD Oncology; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Loxo (Inst); MSD Oncology (Inst)
 
Yuko Kawano
No Relationships to Disclose
 
Tomonari Sasaki
Consulting or Advisory Role - AstraZeneca
 
Hiroyuki Yamaguchi
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly
Research Funding - Boehringer Ingelheim; Lilly; Novartis
 
Katsuya Hirano
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly; Nippon Boehringer Ingelheim
 
Miyako Satouchi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Ignyta (Inst); Lilly Japan (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Shinobu Hosokawa
No Relationships to Disclose
 
Ryotaro Morinaga
No Relationships to Disclose
 
Kazutoshi Komiya
No Relationships to Disclose
 
Koji Inonue
No Relationships to Disclose
 
Yuka Fujita
Speakers' Bureau - Chugai Pharma; Lilly
Research Funding - Chugai Pharma (Inst); Hisamitsu Pharmaceutical (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Ryo Toyozawa
No Relationships to Disclose
 
Tomoki Kimura
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyorin; MSD; Novartis; Ono Pharmaceutical; Pfizer
 
Kosuke Takahashi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; MSD; Novartis; Taiho Pharmaceutical
 
Kazuo Nishikawa
No Relationships to Disclose
 
Junji Kishimoto
No Relationships to Disclose
 
Yoichi Nakanishi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Lilly Japan; MSD; Ono Pharmaceutical; Pfizer
Research Funding - Asahi Kasei (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)